Bristol-Myers Squibb BMY Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's return on equity?
- Bristol-Myers Squibb (BMY) reported return on equity of 38.8% in Q1 2026.
- How has Bristol-Myers Squibb's return on equity changed year-over-year?
- Bristol-Myers Squibb's return on equity increased by 23.1% year-over-year, from 31.6% to 38.8%.
- What is the long-term trend for Bristol-Myers Squibb's return on equity?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's return on equity has grown at a 62.1% compound annual growth rate (CAGR), from -19.4% to 134.4%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.